Everolimus-d4 (CAS 1338452-54-2)
See product citations (2)
QUICK LINKS
Everolimus-d4 is a deuterated version of everolimus, where four hydrogen atoms are replaced with deuterium, a heavier isotope of hydrogen. This modification is of particular interest in the field of analytical chemistry, where isotopic labeling is used to trace the distribution, metabolism, and excretion of compounds without altering their properties. Everolimus-d4 serves as an internal standard for mass spectrometry-based assays. The incorporation of deuterium atoms provides a slight mass difference that allows for the distinct detection of the labeled compound alongside its unlabeled counterpart. Everolimus is a Rapamycin derivative that effectively hinders mTOR signaling through both mTORC1 and mTORC2 when introduced to cells at a concentration of 20 nM. Everolimus demonstrates the ability to inhibit the PI3K/Akt pathway, leading to the suppression of apoptosis and cell survival.
Everolimus-d4 (CAS 1338452-54-2) References
- Ultra fast liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of cyclosporin A, tacrolimus, sirolimus, and everolimus in whole blood using deuterated internal standards for cyclosporin A and everolimus. | Meinitzer, A., et al. 2010. Ther Drug Monit. 32: 61-6. PMID: 20010460
- Comparison of a stable isotope-labeled and an analog internal standard for the quantification of everolimus by a liquid chromatography-tandem mass spectrometry method. | Heideloff, C., et al. 2013. Ther Drug Monit. 35: 246-50. PMID: 23503452
- Two rapid ultra performance liquid chromatography/tandem mass spectrometry (UPLC/MS/MS) methods with common sample pretreatment for therapeutic drug monitoring of immunosuppressants compared to immunoassay. | Tszyrsznic, W., et al. 2013. J Chromatogr B Analyt Technol Biomed Life Sci. 928: 9-15. PMID: 23584041
- A simple and robust LC-MS/MS method for measuring sirolimus and everolimus in whole blood. | Yuan, C., et al. 2014. Bioanalysis. 6: 1597-604. PMID: 25077621
- Possibilities and limitations of signal summing for an immunosuppressant LC-MS/MS method. | Pauwels, S., et al. 2015. Anal Bioanal Chem. 407: 6191-9. PMID: 26072209
- Development and validation of an analytical method using UPLC-MS/MS to quantify everolimus in dried blood spots in the oncology setting. | Knapen, LM., et al. 2018. J Pharm Biomed Anal. 149: 106-113. PMID: 29112898
- Analysis of Immunosuppressant Drugs in Whole Blood by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). | Pablo, AH., et al. 2020. Curr Protoc Toxicol. 84: e92. PMID: 32436620
- Fully Automated Dried Blood Spot Extraction coupled to Liquid Chromatography-tandem Mass Spectrometry for Therapeutic Drug Monitoring of Immunosuppressants. | Deprez, S. and Stove, CP. 2021. J Chromatogr A. 1653: 462430. PMID: 34384960
- Pilot study evaluating everolimus molecular mechanisms in tuberous sclerosis complex and focal cortical dysplasia. | Leitner, DF., et al. 2022. PLoS One. 17: e0268597. PMID: 35587487
- Expression of γ-globin genes in β-thalassemia patients treated with sirolimus: results from a pilot clinical trial (Sirthalaclin). | Zuccato, C., et al. 2022. Ther Adv Hematol. 13: 20406207221100648. PMID: 35755297
- Immunosuppressant Monitoring-Performance of the First Mass Spectrometry-Based Automated Clinical Analyzer Cascadion. | Grote-Koska, D., et al. 2023. Ther Drug Monit. 45: 14-19. PMID: 36301627
- Liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring of immunosuppressants and creatinine from a single dried blood spot using the Capitainer® qDBS device. | Deprez, S., et al. 2023. Anal Chim Acta. 1242: 340797. PMID: 36657891
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Everolimus-d4, 1 mg | sc-218453 | 1 mg | $439.00 |